Cabozantinib (XL184) with panitumamab in KRAS wild-type metastatic colorectal cancer with pharmacodynamic studies, XL184-IST28

Clinical Trial Grant

Duke Scholars

Principal Investigator John Strickler Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Exelixis, Inc

Start Date

April 1, 2014

End Date

April 7, 2021

Administered By

Duke Cancer Institute

Awarded By

Exelixis, Inc

Start Date

April 1, 2014

End Date

April 7, 2021